Progress in alleviating tissue damage and clinical symptoms by inhibiting aggregation in gelsolin amyloidosis could encourage and guide the work among more complex protein misfolding diseases, which pose an enormous burden on innumerable individuals and society. This evidence concerns the gene GSN and proteostasis deficiencies.